Federal Labs May Be an Overlooked Path Into the Defense Market for Commercial Technology

Technology transfer traditionally evokes a familiar image: a federal laboratory develops an invention, patents it, and searches for a private company capable of turning government research into a commercial product.

A different model is gaining attention in national-security technology.

Rather than technology moving only out of federal laboratories, commercially developed technology can increasingly move into the federal laboratory ecosystem for testing, validation, adaptation, and integration.

In a September 17 Federal News Network interview, Federal Laboratory Consortium leaders Paige George and David Lee described this increasingly bidirectional model. Commercial companies—particularly startups and nontraditional contractors—may possess promising technologies but lack the specialized facilities, scientific expertise, testing environments, or government relationships necessary to establish that the technology can satisfy military requirements. Federal laboratories can help bridge that gap.

The implications for federal contractors are significant.

A company with emerging technology often assumes that its principal routes into government are a solicitation, SBIR/STTR award, Other Transaction agreement, subcontract with a defense prime, or direct engagement with an innovation organization such as DIU.

Federal laboratories create another pathway.

The Federal Laboratory Consortium represents a network of more than 300 federal laboratories and facilities and provides resources intended to connect private companies with federal technologies, research expertise, equipment, and partnership opportunities.

One of the most important mechanisms is the Cooperative Research and Development Agreement, or CRADA. Under a CRADA, a federal laboratory can contribute personnel, facilities, equipment, intellectual property, and other resources—although not funding—to collaborative R&D with a nonfederal party.

That distinction matters.

A CRADA is not a procurement contract and does not guarantee a future federal award. But for a company that needs technical validation, access to specialized government facilities, interoperability testing, or direct collaboration with federal scientists and engineers, the value may precede procurement.

The FLC is now institutionalizing this broader concept through its “Innovation for Impact” initiative, which includes an Industry Engagement Day focused on helping companies understand federal laboratory capabilities and partnership mechanisms such as CRADAs.

For nontraditional contractors, this changes the market-entry question.

Instead of asking only, “What contract should we bid?” a technology company might ask: “Which federal laboratory understands the problem our technology solves, and what collaboration mechanism could help us validate the capability before a procurement exists?”

That can be particularly valuable where the barrier is not invention but government acceptance. Technologies may require testing under military conditions, integration with existing platforms, cybersecurity validation, safety evaluation, materials testing, or modification to meet specialized mission requirements.

Companies should nevertheless approach these relationships strategically. Intellectual-property rights, protection of proprietary information, publication, background technology, rights in jointly developed inventions, export controls, and the relationship between laboratory collaboration and future procurement all require careful consideration.

Federal laboratories are not a shortcut around federal acquisition.

But for a commercial company trying to prove that an existing technology can solve a government problem, they may represent an underused bridge between the commercial market and the eventual contract.

Recommended FedContractPros Product: Federal Teaming Strategy Diagnostic Toolkit

The Federal Teaming Strategy Diagnostic Toolkit can help emerging contractors identify capability gaps and determine whether federal laboratories, established primes, technology partners, manufacturers, or other collaborators could strengthen the path from commercial technology to federal-market adoption.

Disclaimer:
This article is provided for general informational and educational purposes only and does not constitute legal, intellectual-property, export-control, technology-transfer, or procurement advice. CRADAs and other federal laboratory agreements are not procurement contracts and do not guarantee future government business. Companies should review the specific agreement, intellectual-property provisions, funding structure, security requirements, and applicable law before entering a collaboration.